Investment
Features
FeesSafety
Academy
More
Pluang+

United Talent Agency leases 100,948 sq ft in Empire State Building, consolidating NYC offices.

Market News
19 Jul 2026
New York Post
View Source
Bullish
pluang ai news

United Talent Agency (UTA) has signed a lease for 100,948 square feet across four floors (32nd to 35th) of the Empire State Building, consolidating its previous 81,000 square feet spread over three Manhattan locations. This move reflects UTA's growth and commitment to New York as a cultural and business hub, supporting its expanding talent representation and brand advisory services. The lease deal highlights the Empire State Building's successful repositioning as a premier office location, nearly fully leased with marquee tenants. UTA's new space offers room for growth and modern amenities, positioning the agency for future expansion in media, sports, and entertainment sectors.

More News

Bankruptcy court approves $470M sale of Oceanwide Plaza, paving way for Downtown LA project completion before 2028 Olympics.

Bankruptcy court approves $470M sale of Oceanwide Plaza, paving way for Downtown LA project completion before 2028 Olympics.

The U.S. Bankruptcy Court for the Central District of California confirmed the Plan of Liquidation for Oceanwide Plaza LLC, enabling the $470 million sale of the stalled Downtown Los Angeles development to KPC Square, a joint venture between KPC Grou...

Company Fundamentals
Bullish
37 minutes ago
Axsome Therapeutics gets 'Outperform' rating on strong drug pipeline and FDA NDA acceptance for narcolepsy drug.

Axsome Therapeutics gets 'Outperform' rating on strong drug pipeline and FDA NDA acceptance for narcolepsy drug.

Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...

Analyst Insights
Bullish
2 hours ago
Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.

Novartis Q2 earnings expected at $2.17 EPS, $14.07B revenue amid patent loss impact and key drug trials ahead.

Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...

Company Fundamentals
Neutral
3 hours ago
KeyCorp expects 20% EPS growth driven by strong loan demand and rising net interest income.

KeyCorp expects 20% EPS growth driven by strong loan demand and rising net interest income.

KeyCorp is set to report earnings with analysts forecasting a 20% increase in earnings per share to $0.42 and an 8% rise in total revenue to $1.97 billion. The growth is mainly driven by a 10% increase in net interest income, fueled by strong commerc...

Company Fundamentals
Bullish
4 hours ago
Biotech and manufacturing stocks plunge after major company shifts and financial concerns.

Biotech and manufacturing stocks plunge after major company shifts and financial concerns.

Several biotech and manufacturing companies saw significant stock declines due to key corporate events. Vision Marine Technologies dropped nearly 24% after shifting its focus from boat manufacturing to a mining project, causing investor uncertainty. ...

Market News
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App